Wen-Jen Hwu

30.6k total citations
67 papers, 2.4k citations indexed

About

Wen-Jen Hwu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Wen-Jen Hwu has authored 67 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 38 papers in Molecular Biology and 19 papers in Immunology. Recurrent topics in Wen-Jen Hwu's work include Melanoma and MAPK Pathways (30 papers), Cutaneous Melanoma Detection and Management (27 papers) and CAR-T cell therapy research (19 papers). Wen-Jen Hwu is often cited by papers focused on Melanoma and MAPK Pathways (30 papers), Cutaneous Melanoma Detection and Management (27 papers) and CAR-T cell therapy research (19 papers). Wen-Jen Hwu collaborates with scholars based in United States, Australia and France. Wen-Jen Hwu's co-authors include Patrick Hwu, Yulia Bronstein, Chaan S. Ng, Agop Y. Bedikian, Nicholas E. Papadopoulos, Kevin B. Kim, Katherine S. Panageas, Jade Homsi, Patrick Hwu and Philip O. Livingston and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Wen-Jen Hwu

67 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wen-Jen Hwu United States 27 1.6k 934 641 555 200 67 2.4k
Merav Leiba Israel 23 930 0.6× 824 0.9× 586 0.9× 139 0.3× 224 1.1× 77 2.0k
Sandrine Aspeslagh Belgium 26 1.4k 0.9× 661 0.7× 843 1.3× 345 0.6× 118 0.6× 89 2.5k
Sangeeta Goswami United States 19 1.2k 0.8× 801 0.9× 1.2k 1.9× 626 1.1× 138 0.7× 57 2.7k
Deborah J. Wong United States 20 1.0k 0.7× 1.2k 1.3× 531 0.8× 503 0.9× 35 0.2× 79 2.4k
Johannes V. van Thienen Netherlands 20 683 0.4× 982 1.1× 471 0.7× 572 1.0× 112 0.6× 63 2.1k
Breanna M. Allen United States 8 702 0.5× 660 0.7× 624 1.0× 236 0.4× 68 0.3× 10 1.8k
Miles C. Andrews Australia 18 1.6k 1.0× 591 0.6× 1.1k 1.7× 360 0.6× 90 0.5× 52 2.4k
Su Yin Lim Australia 28 1.6k 1.0× 1.3k 1.3× 1.4k 2.1× 415 0.7× 79 0.4× 50 3.1k
C. Christian Johansson Sweden 19 590 0.4× 535 0.6× 940 1.5× 108 0.2× 195 1.0× 29 1.7k
Monique B. Nilsson United States 25 1.2k 0.8× 1.2k 1.3× 273 0.4× 807 1.5× 79 0.4× 66 2.5k

Countries citing papers authored by Wen-Jen Hwu

Since Specialization
Citations

This map shows the geographic impact of Wen-Jen Hwu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Jen Hwu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Jen Hwu more than expected).

Fields of papers citing papers by Wen-Jen Hwu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Jen Hwu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Jen Hwu. The network helps show where Wen-Jen Hwu may publish in the future.

Co-authorship network of co-authors of Wen-Jen Hwu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Jen Hwu. A scholar is included among the top collaborators of Wen-Jen Hwu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Jen Hwu. Wen-Jen Hwu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aung, Phyu P., Jun Gu, Priyadharsini Nagarajan, et al.. (2020). TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Modern Pathology. 33(10). 2067–2074. 10 indexed citations
2.
Torres‐Cabala, Carlos A., Denái R. Milton, Doina Ivan, et al.. (2020). Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. Archives of Pathology & Laboratory Medicine. 145(8). 943–952. 13 indexed citations
3.
Kim, Kunhwa, Kunhwa Kim, Carol J. Etzel, et al.. (2018). Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiology. 57. 80–84. 6 indexed citations
4.
Glitza, Isabella C., Michelle Rohlfs, Nandita Guha‐Thakurta, et al.. (2018). Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 3(1). e000283–e000283. 47 indexed citations
5.
Thakar, Sudip, Oded Sagiv, Devjyoti Tripathy, et al.. (2017). Desmoplastic Melanoma of the Periorbital Region. Ophthalmic Plastic and Reconstructive Surgery. 34(2). e48–e52. 2 indexed citations
6.
Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations
7.
Trinh, Van Anh, Chrystia M. Zobniw, & Wen-Jen Hwu. (2017). The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opinion on Drug Safety. 16(8). 933–940. 12 indexed citations
8.
Patel, Sapna P., Dae Won Kim, Roland L. Bassett, et al.. (2017). A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunology Immunotherapy. 66(10). 1359–1366. 26 indexed citations
9.
Eroglu, Zeynep, Dae Won Kim, Xiaoyan Wang, et al.. (2015). Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. European Journal of Cancer. 51(17). 2689–2697. 64 indexed citations
10.
Anderson, Jaime, et al.. (2015). Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma.. PubMed. 19(106). 393–401. 17 indexed citations
11.
Kim, Dae Won, Van Anh Trinh, & Wen-Jen Hwu. (2014). Ipilimumab in the treatment of advanced melanoma – a clinical update. Expert Opinion on Biological Therapy. 14(11). 1709–1718. 9 indexed citations
12.
Davies, Michael A., Patricia S. Fox, Nicholas E. Papadopoulos, et al.. (2012). Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research. 18(4). 1120–1128. 39 indexed citations
13.
Trinh, Van Anh & Wen-Jen Hwu. (2012). Ipilimumab in the treatment of melanoma. Expert Opinion on Biological Therapy. 12(6). 773–782. 19 indexed citations
14.
Patel, Sapna P., Kevin B. Kim, Nicholas E. Papadopoulos, et al.. (2011). A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Research. 21(4). 357–363. 30 indexed citations
15.
Homsi, Jade, Agop Y. Bedikian, Kevin B. Kim, et al.. (2009). Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Research. 19(4). 238–242. 20 indexed citations
16.
Bedikian, Agop Y., Nicholas E. Papadopoulos, Kevin B. Kim, et al.. (2009). A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma. Cancer Investigation. 27(7). 756–763. 52 indexed citations
17.
Bedikian, Agop Y., Marcella M. Johnson, Carla L. Warneke, et al.. (2008). Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma. Cancer Investigation. 26(6). 624–633. 57 indexed citations
18.
Wolchok, Jedd D., Linda Williams, John T. Pinto, et al.. (2003). Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Research. 13(2). 189–196. 34 indexed citations
19.
Lamb, Lynne, Allan C. Halpern, & Wen-Jen Hwu. (2003). Diagnosis and management of stage I/II melanoma. Seminars in Oncology Nursing. 19(1). 22–31. 4 indexed citations
20.
Hwu, Wen-Jen, Jeffery J. Raizer, Katherine S. Panageas, & Eric Lis. (2001). Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. The Lancet Oncology. 2(10). 634–635. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Merav Leiba Breakdown of academic impact, for papers by Sandrine Aspeslagh Breakdown of academic impact, for papers by Sangeeta Goswami Breakdown of academic impact, for papers by Deborah J. Wong Breakdown of academic impact, for papers by Johannes V. van Thienen Breakdown of academic impact, for papers by Breanna M. Allen Breakdown of academic impact, for papers by Miles C. Andrews Breakdown of academic impact, for papers by Su Yin Lim Breakdown of academic impact, for papers by C. Christian Johansson Breakdown of academic impact, for papers by Monique B. Nilsson
Rankless by CCL
2026